id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1167-0027,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Availability,Notice,Notice of Availability,2024-03-18T04:00:00Z,2024,3,,,2024-03-20T12:35:59Z,2024-05687,0,0,09000064864808b5
FDA-2014-D-1167-0028,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry,Other,Guidance,2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2025-04-17T16:24:57Z,,1,0,0900006486481276